NDA 021214 · Sucampo Pharma LLC
Rescula
Unoprostone Isopropyl · Ophthalmic
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 10, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Aug 3, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 3, 2000 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewLetter
1 products under this application
- RESCULA · UNOPROSTONE ISOPROPYL 0.15% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION/DROPS, OPHTHALMIC · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Unoprostone Isopropyl" as an intervention, any sponsor and status, largest first.
- Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis PigmentosaPivotal-lookingTerminated
R-Tech Ueno, Ltd.Industry
NCT01786395 · 202 participants · Start Mar 2013 · Primary completion Apr 2015
Drug: UF-021; Placebo · For: Retinitis Pigmentosa
Sites: Nagoya, Japan; Hirosaki, Japan; Chiba, Japan · 34 sites in all
Sucampo Pharma Americas, LLCIndustry
NCT01379560 · 33 participants · Start May 2011 · Primary completion Dec 2011
Drug: unoprostone isopropyl; unoprostone isopropyl · For: Dry Age-related Macular Degeneration
Sites: Vienna, Austria
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis.
Yang TK, Kuo HT, Ju YJ, et al. · Clin Exp Ophthalmol 2025 · Systematic Review, Comparative Study
- [Clinical evaluation of isopropyl unoprostone (Rescula), in the adjunctive treatment of primary open angle glaucoma].
Zarnowski T, Kawa P, Jurkowska-Dudziska J, et al. · Klin Oczna 2001 · Clinical Trial
- Medical therapy cost considerations for glaucoma.
Fiscella RG, Green A, Patuszynski DH, et al. · Am J Ophthalmol 2003 · Clinical Trial, Comparative Study
- Substituting latanoprost (Xalatan) for isopropyl unoprostone (Rescula) in monotherapy and combination therapy.
Tsukamoto H, Yokoyama T, Okada K, et al. · Acta Ophthalmol Scand 2000 · Clinical Trial, Controlled Clinical Trial
- Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.
Stewart WC, Sharpe ED, Stewart JA, et al. · Am J Ophthalmol 2001 · Clinical Trial, Comparative Study
- A comparison of intraocular pressure-lowering effect of prostaglandin F2 -alpha analogues, latanoprost, and unoprostone isopropyl.
Kobayashi H, Kobayashi K, Okinami S · J Glaucoma 2001 · Clinical Trial, Comparative Study
Sponsor: Sucampo Pharma LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.